new inhaled afrezza for diabetes

Diabetes is a disease of the era, Which requires numerous studies and research in order

 to overcome it.

Now offer you a new drug  and confirmed by U.S. Food and Drug Administration . it is afrezza

(insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic

control in adults with Type 1 and Type 2 diabetes mellitus. Afrezza is a rapid-acting

inhaled insulin that is administered at the beginning of each meal.

given at the start of a meal, AFREZZA dissolves immediately upon inhalation and delivers

 insulin quickly to the blood stream. Peak insulin levels are achieved within 12 to 15

minutes of administration, mimicking the release of mealtime insulin observed in healthy 

individuals. 

Afrezza is not a substitute for long-acting

insulin. Afrezza must be used in combination

with long-acting insulin in patients with type 1

diabetes, and it is not recommended for the

treatment of diabetic ketoacidosis, or in

patients who smoke.

Afrezza has the following outcomes:

Proven reductions in HbA1c

A reduced risk of hypoglycemia vs. rapid-acting analogs

Less weight gain vs. rapid-acting analogs

Injection-free insulin delivery

the likely present side effect a mild, transient, non-productive cough.